跳至主要内容
临床试验/NCT02679989
NCT02679989已完成不适用

A Randomised Controlled Trial Assessing The Impact Of An Intermittent Energy Restricted Diet On Weight Loss, Insulin Sensitivity and Heart Rate Variability In Men and Women With Central Obesity

King's College London2 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2016年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
42
试验地点
2
主要终点
RQUICKI

研究概览

简要总结

An intermittent energy restricted (IER) diet may modify cardio-metabolic disease risk factors compared to an energy-matched continuous energy restricted (CER) diet. A randomised controlled parallel design trial will determine the impact of a short-term IER diet (2 consecutive days of very low calorie diet (VLCD), 5 days moderate energy restriction each week for a 4 week period), compared to a CER diet, on insulin sensitivity in healthy (disease-free) subjects with central obesity.

详细描述

Prediabetes rates in England have showed a marked increase, more than tripling between 2003 and 2011. It is characterised by an impaired fasting glucose or impaired glucose tolerance that increases the risk of progression to type 2 diabetes (T2D). It has been estimated that approximately 90% of T2D is attributed to excess weight. Central obesity is a primary driver of increased cardiometabolic risk due to its lipotoxicity effects, promoting a proinflammatory state that facilitates insulin resistance and beta cell dysfunction. A high waist circumference measurement, indicative of central obesity, is associated with increased risk of cardiovascular diseases and T2D, and is a stronger predictor of T2D than BMI. BMI has limitations as an indicator of adiposity since it doesn't distinguish lean from fat mass, and does not indicate body fat distribution. Conventionally, continuous energy restriction (CER) diets have been used for weight loss, which consist of a constant daily energy deficit relative to total energy expenditure. The impact on weight loss and health of an intermittent energy restriction (IER) approach has only rarely been investigated (although the "5:2 diet" has been popularised in lifestyle books aimed at the general public). An IER diet consists of a predefined period of time severely restricting energy intake, alternated with a period of greater energy intake. This approach was shown to confer metabolic benefits in overweight and obese women at risk of breast cancer with baseline BMI of 2445 (Harvie et al., 2013; Harvie et al., 2011).

Rationale: An IER diet using meal replacements (VLCD foodpacks used as total dietary replacements for 2 consecutive days each week, and a food-based energy-restricted diet for the other 5 days of the week) may modify cardio-metabolic disease risk factors compared to an energy-matched CER diet.

Research question: In centrally obese subjects, assessed by a high waist circumference measurement, does adherence to an IER diet have enhanced cardio-metabolic benefits compared to a CER diet? Hypothesis: Increases in insulin sensitivity following a 4 week dietary intervention with an IER weight loss programme will be greater compared to a standard CER programme.

Objectives:

  1. A randomised controlled parallel design trial will determine the impact of a short-term IER diet compared to a CER diet on primary outcome variables (insulin sensitivity) in healthy subjects with a high waist circumference.
  2. To assess the impact of an IER diet on secondary outcome variables, including body composition, heart rate variability (HRV, a measure of cardiac autonomic function, including parasympathetic and sympathetic activity), blood pressure, vascular function, other markers of insulin resistance, inflammation/adipokines, plasma lipid profile, plasma norepinephrine, ketosis, the gut microbiome and cognitive function in healthy subjects with a high waist circumference.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
35 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged >35-75 years
  • Waist circumference above cut-off for high risk of cardio-metabolic disease of >102 cm in men with a Europid, Black African and Caribbean, and other ethnic background and >88 cm in women with a Europid, Black African and Caribbean, and other ethnic background (WHO, 2008), and ≥90 cm in men and ≥80 cm in women with an Asian background (South Asian and East Asian) (Misra et al., 2009).
  • REFERENCES Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. (2009). Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. The Journal of the Association of Physicians of India 57:
  • WHO (2008). Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva, 8-11 December 2008.

排除标准

  • Kidney or cardiovascular disease, cancer, diabetes, gastrointestinal or chronic liver disease;
  • previous bariatric surgery or other major surgery (e.g. organ transplantation);
  • unable to provide written informed consent;
  • have significant psychiatric disorder (e.g. schizophrenia, anxiety, panic disorder, attention deficit disorder, post-traumatic stress disorder, obsessive compulsive disorder) or uncontrolled depression;
  • participated in a weight management drug trial in the previous 3 months;
  • have binge eating behaviour;
  • have uncontrolled epilepsy;
  • alcohol or substance abuse;
  • currently pregnant, lactating, or planning pregnancy within the study period;
  • are using medication clinically deemed to affect metabolic rate and weight (e.g. beta blockers, corticosteroids, diuretics, etc);
  • lactose intolerant.

结局指标

主要结局

RQUICKI

时间窗: day 31

Marker of insulin sensitivity

Revised QUICKI (RQUICKI)

时间窗: Baseline

Marker of insulin sensitivity

次要结局

  • Plasma leptin concentration(day 31)
  • Waist circumference(day 31)
  • Percentage lean body mass(day 31)
  • Heart rate variability (resting)(day 31)
  • Plasma non-esterified fatty acid concentration(day 31)
  • Plasma insulin concentration(day 31)
  • Plasma total cholesterol concentration(day 31)
  • Homeostasis model assessment estimated insulin resistance (HOMA-IR)(day 31)
  • Plasma low density lipoprotein (LDL) cholesterol concentration(Baseline)
  • Plasma triglyceride concentration(day 31)
  • Body mass index (BMI)(Baseline)
  • Hip circumference(day 31)
  • Ambulatory blood pressure daytime(Daytime analysis on day 31)
  • Ambulatory blood pressure night-time(Night-time analysis on day 31)
  • Mnemonic Similarity Test(day 31)
  • Plasma glucose concentration(day 31)
  • Plasma LDL cholesterol concentration(day 31)
  • Plasma HDL cholesterol concentration(day 31)
  • Plasma soluble alpha-klotho concentration(day 31)
  • Body weight(day 31)
  • Heart rate variability (ambulatory)(24 h recording on day 31)
  • Heart rate variability (sleep-time)(day 31)
  • Digital volume pulse - stiffness index (SI)(Baseline)
  • Digital volume pulse - SI(day 31)
  • Plasma high density lipoprotein (HDL) cholesterol concentration(Baseline)
  • BMI(day 31)
  • Ambulatory blood pressure 24 h(24 h analysis on day 31)
  • Digital volume pulse - RI(day 31)
  • Power of food scale(day 31)
  • Plasma total cholesterol:HDL cholesterol ratio(day 31)
  • Plasma adiponectin concentration(day 31)
  • Plasma interleukin-6 concentration(day 31)
  • Plasma beta-hydroxybutyrate concentration(day 31)
  • Plasma norepinephrine concentration(day 31)
  • Percentage body fat(day 31)
  • COPE (not an acronym)(Baseline)
  • COPE(day 31)
  • Heart rate variability (during mental stress)(day 31)
  • Digital volume pulse - reflection index (RI)(Baseline)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

The Impact Of An Intermittent Energy Restricted Diet... | 临床试验